Eprenetapopt (APR-246) and Azacitidine in TP53-Mutant Myelodysplastic Syndromes
نویسندگان
چکیده
منابع مشابه
Safety and efficacy of azacitidine in myelodysplastic syndromes
PURPOSE The clinical efficacy, different dosages, treatment schedules, and safety of azacitidine are reviewed. SUMMARY Azacitidine is the first drug FDA-approved for the treatment of myelodysplastic syndromes that has demonstrated improvements in overall survival and delaying time to progression to acute myelogenous leukemia. The recommended dosage of azacitidine is 75 mg/m(2) daily for 7 day...
متن کاملTP53 and Decitabine in Acute Myeloid Leukemia and Myelodysplastic Syndromes.
BACKGROUND The molecular determinants of clinical responses to decitabine therapy in patients with acute myeloid leukemia (AML) or myelodysplastic syndromes (MDS) are unclear. METHODS We enrolled 84 adult patients with AML or MDS in a single-institution trial of decitabine to identify somatic mutations and their relationships to clinical responses. Decitabine was administered at a dose of 20 ...
متن کاملAzacitidine for the treatment of myelodysplastic syndromes (MDS).pub
Azacitidine is a pyrimidine nucleoside analogue with multiple mechanisms involved in its antineoplastic action. There is evidence that RNA metabolism is the primary target of this antimetabolite, although its inhibition of DNA methylation has been proposed as the main effect responsible for its clinical efficacy in myelodysplastic syndromes. In patients with myelodysplastic syndromes (MDS), aza...
متن کاملThe relationship of TP53 R72P polymorphism to disease outcome and TP53 mutation in myelodysplastic syndromes
Nonsynonymous TP53 exon 4 single-nucleotide polymorphism (SNP), R72P, is linked to cancer and mutagen susceptibility. R72P associations with specific cancer risk, particularly hematological malignancies, have been conflicting. Myelodysplastic syndrome (MDS) with chromosome 5q deletion is characterized by erythroid hypoplasia arising from lineage-specific p53 accumulation resulting from ribosoma...
متن کاملStrong synergy with APR-246 and DNA-damaging drugs in primary cancer cells from patients with TP53 mutant High-Grade Serous ovarian cancer.
BACKGROUND Mutation in the tumor suppressor gene TP53 is an early event in the development of high-grade serous (HGS) ovarian cancer and is identified in more than 96 % of HGS cancer patients. APR-246 (PRIMA-1(MET)) is the first clinical-stage compound that reactivates mutant p53 protein by refolding it to wild type conformation, thus inducing apoptosis. APR-246 has been tested as monotherapy i...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Journal of Clinical Oncology
سال: 2021
ISSN: 0732-183X,1527-7755
DOI: 10.1200/jco.20.02341